Com-COV2 study supports flexible second dose options following Pfizer or Oxford/AstraZeneca jabs


Monday 6th Dec 2021, 11.27pm

Following up first doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines with second doses of the Moderna or Novavax jabs will generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.